Statistically significant improvements in lung function, symptoms and quality of life 36% reduction in rate of exacerbations over 24 weeks Well tolerated safety profile over 48 weeks NDA submission planned for 1H 2023
We are focused on treating respiratory diseases with significant unmet medical needs, such as COPD, cystic fibrosis and asthma. The Company is listed on the Nasdaq Global Market in the United States under the VRNA ticker.
The condition causes loss of lung function, hospitalizations and death. COPD affects approximately 384 million people worldwide. It is the third leading cause of death globally, according to the Global Initiative for Chronic Obstructive Lung Disease.Find out more
May 9 2023
© Verona Pharma plc 2023. All rights reserved